New England Journal of Medicine· 2018Q1· Clinical trial
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- 4,667citations
- Q1SCImago
- 2018year
Short summary
Combining nivolumab and ipilimumab significantly improved overall survival and objective response rates compared to sunitinib in previously untreated advanced renal-cell carcinoma patients with intermediate or poor risk.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine